Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
67.49(c) 67.72(c) 68.14(c) 67.35(c) 65.57(c) Last
8 927 172 5 866 961 6 447 991 6 198 428 8 209 190 Volume
-0.97% +0.34% +0.62% -1.16% -2.64% Change
More quotes
Financials (USD)
Sales 2018 21 769 M
EBIT 2018 11 789 M
Net income 2018 7 221 M
Debt 2018 9 502 M
Yield 2018 3,50%
Sales 2019 21 645 M
EBIT 2019 11 608 M
Net income 2019 7 373 M
Debt 2019 9 017 M
Yield 2019 3,81%
P/E ratio 2018 11,89
P/E ratio 2019 11,54
EV / Sales2018 4,33x
EV / Sales2019 4,34x
Capitalization 84 823 M
More Financials
Company
Gilead Sciences specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.3%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (90.9% of net sales) and other (9.1%; primarily... 
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
12/13GILEAD SCIENCES : Ex-dividend day for
FA
12/11GILEAD SCIENCES : Names Daniel O'Day Chairman and Chief Executive Officer
AQ
12/11GILEAD SCIENCES : Roche's O'Day to lead Gilead
AQ
12/11GILEAD SCIENCES : snares Roche veteran Daniel O'Day as its new chief executive
AQ
12/10GILEAD SCIENCES INC : Change in Directors or Principal Officers, Financial State..
AQ
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10Roche Pharmaceuticals Names New CEO as O'Day Leaves to Head Gilead -- Update
DJ
12/10Roche Executive Named Gilead CEO -- 2nd Update
DJ
12/10Gilead Taps Roche Veteran as New CEO -- WSJ
DJ
12/10GILEAD SCIENCES : Names Daniel O'Day Chairman and Chief Executive Officer
BU
More news
Analyst Recommendations on GILEAD SCIENCES
More recommendations
Sector news : Bio Therapeutic Drugs
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
12/08Moderna Declines in Market Debut -- WSJ
DJ
More sector news : Bio Therapeutic Drugs
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 87,0 $
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES-8.47%84 823
VERTEX PHARMACEUTICALS15.72%43 460
REGENERON PHARMACEUTICALS1.39%40 527
GENMAB3.84%9 952
SAREPTA THERAPEUTICS INC114.81%7 987
NEUROCRINE BIOSCIENCES, INC.-8.06%6 469